Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Neurocrine Biosciences In...

    NASDAQ: NBIX · Real-Time Price · USD
    125.30
    0.91 (0.73%)
    At close: Jun 16, 2025, 3:59 PM
    125.00
    -0.24%
    Pre-market: Jun 17, 2025, 04:18 AM EDT

    Neurocrine Biosciences Statistics

    Share Statistics

    Neurocrine Biosciences has 98.97M shares outstanding. The number of shares has increased by -0.93% in one year.

    Shares Outstanding

    n/a
    		 98.97M

    Shares Change (YoY)

    n/a
    		 -0.93%

    Shares Change (QoQ)

    n/a
    		 -1.52%

    Owned by Institutions (%)

    n/a
    		 94%

    Shares Floating

    n/a
    		 95.47M

    Failed to Deliver (FTD) Shares

    n/a
    		 9,365

    FTD / Avg. Volume

    n/a
    		 0.64%

    Short Selling Information

    The latest short interest is 4.06M, so 4.11% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.06M

    Short % of Shares Out

    n/a
    		 4.11%

    Short % of Float

    n/a
    		 5.48%

    Short Ratio (days to cover)

    n/a
    		 3.76

    Valuation Ratios

    The PE ratio is 40.15 and the forward PE ratio is 20.88. Neurocrine Biosciences's PEG ratio is 1.22.

    PE Ratio

    n/a
    		 40.15

    Forward PE

    n/a
    		 20.88

    PS Ratio

    n/a
    		 5.82

    Forward PS

    n/a
    		 3

    PB Ratio

    n/a
    		 5.29

    P/FCF Ratio

    n/a
    		 24.6

    PEG Ratio

    n/a
    		 1.22
    Financial Ratio History

    Enterprise Valuation

    Neurocrine Biosciences has an Enterprise Value (EV) of 13.93B.

    EV / Sales

    n/a
    		 5.91

    EV / EBITDA

    n/a
    		 21.77

    EV / EBIT

    n/a
    		 23.39

    EV / FCF

    n/a
    		 24.99

    Financial Position

    The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.18.

    Current Ratio

    n/a
    		 3.4

    Quick Ratio

    n/a
    		 3.28

    Debt / Equity

    n/a
    		 0.18

    Debt / EBITDA

    n/a
    		 0.71

    Debt / FCF

    n/a
    		 0.82

    Interest Coverage

    n/a
    		 4.51

    Financial Efficiency

    Return on Equity is 13.18% and Return on Invested Capital is 12.48%.

    Return on Equity

    n/a
    		 13.18%

    Return on Assets

    n/a
    		 9.18%

    Return on Invested Capital

    n/a
    		 12.48%

    Revenue Per Employee

    n/a
    		 $1,308,500

    Profits Per Employee

    n/a
    		 $189,611.11

    Employee Count

    n/a
    		 1,800

    Asset Turnover

    n/a
    		 0.63

    Inventory Turnover

    n/a
    		 0.59

    Taxes

    Income Tax

    n/a
    		 144.7M

    Effective Tax Rate

    n/a
    		 29.77%

    Stock Price Statistics

    The stock price has increased by -7.38% in the last 52 weeks. The beta is 0.24, so Neurocrine Biosciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.24

    52-Week Price Change

    n/a
    		 -7.38%

    50-Day Moving Average

    n/a
    		 113.07

    200-Day Moving Average

    n/a
    		 121.3

    Relative Strength Index (RSI)

    n/a
    		 62.03

    Average Volume (20 Days)

    n/a
    		 1,454,792

    Income Statement

    In the last 12 months, Neurocrine Biosciences had revenue of 2.36B and earned 341.3M in profits. Earnings per share was 3.4.

    Revenue

    n/a
    		 2.36B

    Gross Profit

    n/a
    		 2.32B

    Operating Income

    n/a
    		 570.5M

    Net Income

    n/a
    		 341.3M

    EBITDA

    n/a
    		 639.7M

    EBIT

    n/a
    		 612.6M

    Earnings Per Share (EPS)

    n/a
    		 3.4
    Full Income Statement

    Balance Sheet

    The company has 233M in cash and 455.1M in debt, giving a net cash position of -222.1M.

    Cash & Cash Equivalents

    n/a
    		 233M

    Total Debt

    n/a
    		 455.1M

    Net Cash

    n/a
    		 -222.1M

    Retained Earnings

    n/a
    		 29.2M

    Total Assets

    n/a
    		 3.69B

    Working Capital

    n/a
    		 1.11B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 595.4M and capital expenditures -38.2M, giving a free cash flow of 557.2M.

    Operating Cash Flow

    n/a
    		 595.4M

    Capital Expenditures

    n/a
    		 -38.2M

    Free Cash Flow

    n/a
    		 557.2M

    FCF Per Share

    n/a
    		 5.55
    Full Cash Flow Statement

    Margins

    Gross margin is 98.56%, with operating and profit margins of 24.22% and 14.49%.

    Gross Margin

    n/a
    		 98.56%

    Operating Margin

    n/a
    		 24.22%

    Pretax Margin

    n/a
    		 20.63%

    Profit Margin

    n/a
    		 14.49%

    EBITDA Margin

    n/a
    		 27.16%

    EBIT Margin

    n/a
    		 24.22%

    FCF Margin

    n/a
    		 23.66%

    Dividends & Yields

    NBIX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 2.49%

    FCF Yield

    n/a
    		 4.07%
    Dividend Details

    Analyst Forecast

    The average price target for NBIX is $159, which is 26.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $159

    Price Target Difference

    n/a
    		 26.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 20
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $17

    Lynch Upside

    n/a
    		 -86.43%

    Graham Number

    n/a
    		 44.42

    Graham Upside

    n/a
    		 -64.55%

    Scores

    Altman Z-Score

    n/a
    		 7.86

    Piotroski F-Score

    n/a
    		 8

    Add to Watchlist